What We’re Reading: Licensing COVID-19 Pill; Pig-to-Human Transplants; Blood Tube Shortage
Drug makers sign on to help produce Merck’s COVID-19 pill for developing countries; research shows promise for organ transplants from genetically modified pigs; blood sample collection tubes added to FDA list of shortages.
CYNK-101 Receives Fast Track Designation for HER2-Positive Gastric/GEJ Cancers
Natural killer cell therapy CYNK-101 was granted fast track designation by the FDA to treat HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with standard chemotherapy, trastuzumab, and pembrolizumab.
Lack of Monitoring Among Older Patients With CML Linked to Poor TKI Adherence
The findings showing that older patients with chronic myeloid leukemia (CML) had poor adherence to tyrosine kinase inhibitors (TKIs) was presented last month during the American Society of Hematology Meeting & Exposition.
Hortobagyi Discusses MONALEESA-2 and the Importance of Overall Survival in Breast Cancer Care
In a career spanning 45 years, Gabriel N. Hortobagyi, MD, has seen the number of cancer therapies increase from 8-10 for all of oncology to more than 400. Here, he discusses the importance of overall survival in breast cancer as seen in the MONALEESA-2 trial.
FCS’ Bailey Discusses 4-Drug Regimens, Use of MRD in Multiple Myeloma
Ray Bailey, BPharm, RPh, senior vice president of Pharmacy Services for Florida Cancer Specialists (FCS) Pharmacy Services operations, spoke with The American Journal of Managed Care® (AJMC®) just after the conclusion of the 63rd American Society of Hematology Meeting & Exposition, which took place December 11-14, 2021.
ACCC Presents Survey Responses on Adoption of Bispecific Antibodies
ACCC created a survey to better understand multidisciplinary cancer providers’ experiences with bispecific antibodies, with a focus on experiences with blinatumomab. Results of the survey were presented in an abstract during the 2021 American Society of Hematology Annual Meeting & Exposition.